v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Total Revenue $ 95,577 $ 63,423
COST OF REVENUE 48,462 36,120
GROSS PROFIT 47,115 27,303
Operating expenses:    
General and administrative 32,142 17,067
Research and development 1,209 956
Sales and marketing 11,216 6,775
Total operating expenses 44,567 24,798
INCOME FROM OPERATIONS 2,548 2,505
Interest expense, net 1,826 1,486
Other expense (income) (5,169) 63
Income (loss) before taxes (4,447) 1,082
Income tax (benefit) expense (2,023) 438
NET INCOME (LOSS) (2,424) 644
Deemed dividends on preferred stock 0 1,003
Amortization of preferred stock beneficial conversion feature 0 1,853
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,424) $ (2,212)
INCOME (LOSS) PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS    
Basic (in dollars per share) $ (0.03) $ (0.03)
Diluted (in dollars per share) $ (0.03) $ (0.03)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (in shares) 94,740 80,507
Diluted (in shares) 94,740 80,507
Clinical Services    
Total Revenue $ 86,210 $ 56,971
GROSS PROFIT 43,559 25,929
Pharma Services    
Total Revenue 9,367 6,452
GROSS PROFIT $ 3,556 $ 1,374

Source